Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rosacea | 7 | 2023 | 49 | 5.380 |
Why?
|
| Skin Diseases | 6 | 2022 | 1065 | 2.480 |
Why?
|
| Dermatology | 6 | 2023 | 872 | 1.780 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2022 | 153 | 1.490 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 654 | 1.070 |
Why?
|
| Psoriasis | 3 | 2022 | 898 | 1.000 |
Why?
|
| Epigenesis, Genetic | 4 | 2022 | 3647 | 0.920 |
Why?
|
| Ostomy | 1 | 2021 | 27 | 0.810 |
Why?
|
| Surgical Stomas | 1 | 2021 | 43 | 0.790 |
Why?
|
| Skin | 7 | 2022 | 4364 | 0.760 |
Why?
|
| Masseter Muscle | 1 | 2019 | 36 | 0.690 |
Why?
|
| Granuloma Annulare | 1 | 2019 | 28 | 0.690 |
Why?
|
| Consumer Health Information | 1 | 2021 | 211 | 0.670 |
Why?
|
| Dicarboxylic Acids | 1 | 2018 | 69 | 0.650 |
Why?
|
| Eyebrows | 1 | 2018 | 28 | 0.630 |
Why?
|
| Hair Removal | 1 | 2018 | 42 | 0.610 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 2425 | 0.600 |
Why?
|
| Nonprescription Drugs | 1 | 2018 | 116 | 0.600 |
Why?
|
| Metronidazole | 1 | 2018 | 217 | 0.600 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 134 | 0.600 |
Why?
|
| Hypertrophy | 1 | 2019 | 569 | 0.590 |
Why?
|
| Herpes Zoster | 1 | 2019 | 264 | 0.580 |
Why?
|
| Aminoquinolines | 1 | 2016 | 109 | 0.570 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 207 | 0.540 |
Why?
|
| Facial Neoplasms | 1 | 2016 | 121 | 0.540 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2019 | 213 | 0.540 |
Why?
|
| Lasers, Gas | 1 | 2016 | 93 | 0.520 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 278 | 0.500 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 241 | 0.480 |
Why?
|
| DNA Methylation | 4 | 2022 | 4286 | 0.480 |
Why?
|
| Telemedicine | 3 | 2021 | 2872 | 0.470 |
Why?
|
| Petrolatum | 1 | 2012 | 8 | 0.450 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 1170 | 0.440 |
Why?
|
| Self Care | 1 | 2018 | 786 | 0.440 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 789 | 0.440 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 604 | 0.430 |
Why?
|
| Acne Vulgaris | 3 | 2022 | 302 | 0.430 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5686 | 0.410 |
Why?
|
| Prescription Drugs | 1 | 2018 | 595 | 0.390 |
Why?
|
| Urticaria | 1 | 2012 | 150 | 0.390 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 972 | 0.380 |
Why?
|
| Cost of Illness | 1 | 2020 | 1859 | 0.370 |
Why?
|
| Telomere-Binding Proteins | 1 | 2010 | 116 | 0.360 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 1912 | 0.350 |
Why?
|
| Cosmetic Techniques | 2 | 2023 | 135 | 0.350 |
Why?
|
| Crohn Disease | 1 | 2022 | 2303 | 0.340 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 1671 | 0.330 |
Why?
|
| Water | 1 | 2012 | 1395 | 0.270 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 594 | 0.270 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3133 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3240 | 0.260 |
Why?
|
| Telomere | 1 | 2010 | 910 | 0.240 |
Why?
|
| Humans | 36 | 2023 | 744343 | 0.230 |
Why?
|
| Pandemics | 2 | 2020 | 8388 | 0.220 |
Why?
|
| Isotretinoin | 1 | 2023 | 114 | 0.210 |
Why?
|
| Sebum | 1 | 2021 | 16 | 0.210 |
Why?
|
| Erythema | 1 | 2023 | 257 | 0.200 |
Why?
|
| Skin Care | 1 | 2021 | 49 | 0.200 |
Why?
|
| Inflammation | 1 | 2021 | 10638 | 0.190 |
Why?
|
| DNA Repair | 1 | 2010 | 2046 | 0.190 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2010 | 1888 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2016 | 3309 | 0.190 |
Why?
|
| Research Design | 1 | 2016 | 5987 | 0.190 |
Why?
|
| Lasers, Dye | 1 | 2020 | 29 | 0.190 |
Why?
|
| Ecchymosis | 1 | 2020 | 32 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2915 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2021 | 21746 | 0.170 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2020 | 79 | 0.170 |
Why?
|
| Pigmentation Disorders | 1 | 2019 | 101 | 0.170 |
Why?
|
| Melanosis | 1 | 2019 | 78 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 789 | 0.170 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2019 | 131 | 0.160 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 552 | 0.150 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 169 | 0.150 |
Why?
|
| Mastocytosis | 1 | 2019 | 160 | 0.150 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2019 | 252 | 0.150 |
Why?
|
| Comorbidity | 2 | 2021 | 10388 | 0.140 |
Why?
|
| Face | 2 | 2021 | 994 | 0.140 |
Why?
|
| Genes, cdc | 1 | 2007 | 116 | 0.140 |
Why?
|
| Models, Organizational | 1 | 2020 | 574 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 230 | 0.140 |
Why?
|
| Histones | 2 | 2021 | 2599 | 0.140 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2007 | 232 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2022 | 9146 | 0.130 |
Why?
|
| Dermatitis | 1 | 2017 | 197 | 0.130 |
Why?
|
| Hair | 1 | 2018 | 483 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2023 | 63114 | 0.120 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2013 | 42 | 0.120 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 453 | 0.120 |
Why?
|
| Tretinoin | 1 | 2007 | 517 | 0.120 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 857 | 0.120 |
Why?
|
| Lasers | 1 | 2018 | 952 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13695 | 0.110 |
Why?
|
| Cryoglobulinemia | 1 | 2013 | 87 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 966 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2019 | 1072 | 0.110 |
Why?
|
| Histamine H1 Antagonists | 1 | 2012 | 100 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2023 | 5788 | 0.100 |
Why?
|
| Microscopy | 1 | 2016 | 903 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 4420 | 0.100 |
Why?
|
| Replication Protein A | 1 | 2010 | 52 | 0.090 |
Why?
|
| Cell Separation | 1 | 2016 | 1751 | 0.090 |
Why?
|
| Melanoma | 2 | 2019 | 5510 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3610 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2022 | 3528 | 0.090 |
Why?
|
| Endodeoxyribonucleases | 1 | 2010 | 165 | 0.090 |
Why?
|
| Vasculitis | 1 | 2013 | 519 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2010 | 180 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2022 | 8324 | 0.090 |
Why?
|
| Binding, Competitive | 1 | 2010 | 1157 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2022 | 77449 | 0.080 |
Why?
|
| Cell Communication | 1 | 2016 | 1621 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 931 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2022 | 4558 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 1031 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 1524 | 0.060 |
Why?
|
| Neutrophils | 1 | 2017 | 3719 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8642 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 15540 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 19905 | 0.060 |
Why?
|
| DNA Replication | 1 | 2010 | 1399 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8664 | 0.060 |
Why?
|
| Propionibacterium acnes | 1 | 2022 | 66 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 3712 | 0.050 |
Why?
|
| Swimming | 1 | 2021 | 206 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2016 | 19229 | 0.050 |
Why?
|
| Aged | 3 | 2022 | 163280 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 2752 | 0.040 |
Why?
|
| Female | 4 | 2023 | 380194 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 954 | 0.040 |
Why?
|
| Histone Acetyltransferases | 1 | 2019 | 336 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 1085 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 399 | 0.030 |
Why?
|
| Granulocytes | 1 | 2017 | 548 | 0.030 |
Why?
|
| G1 Phase | 1 | 2007 | 415 | 0.030 |
Why?
|
| Male | 5 | 2023 | 350118 | 0.030 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2013 | 8 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 57776 | 0.030 |
Why?
|
| United States | 1 | 2022 | 69872 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 72290 | 0.030 |
Why?
|
| Adolescent | 3 | 2022 | 85781 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 1588 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 1097 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 16689 | 0.020 |
Why?
|
| Middle Aged | 3 | 2020 | 213383 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2019 | 2967 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 693 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 1783 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 20822 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 4217 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2727 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 2849 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 214055 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2013 | 1379 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 29786 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 168757 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10481 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8428 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 12959 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29063 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 23403 | 0.010 |
Why?
|
Concepts
(163)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(18)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_